Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Geron To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $100,000 in Geron between February 28, 2024 to February 25, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, March 28, 2025 /PRNewswir ...

LOS ANGELES, March 28, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Geron Corporation ("Geron" or "the Company") (NASDAQ: GERN) for violations of the federal securities laws.Shareholders who purchased the Company's securities between June 7, 2024 and February 25, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before May 12, 2025.     CASE DETAILS:  According to the Complaint the company allegedly made misleading statements that gave inv ...

NEW YORK, March 28, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Geron Corporation ("Geron" or the "Company") (NASDAQ: GERN) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Geron investors who were adversely affected by alleged securities fraud between June 7, 2024 and February 25, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/geron-corporation-lawsuit-submission ...

Core Viewpoint - A class action lawsuit has been filed against Geron Corporation for allegedly misleading investors about the launch and growth potential of its drug Rytelo, a telomerase inhibitor for blood cancer treatment [1][2][3]. Allegations - The lawsuit claims that Geron did not disclose that the optimistic reports regarding Rytelo's launch success were not reflective of reality, as factors like seasonality, competition, and monitoring burdens significantly impacted patient starts [3]. - It is alleged that Rytelo lacked sufficient market awareness, hindering Geron's ability to meet the unmet need for the drug, especially among first-line patients and those outside academic settings [3]. Financial Impact - On February 26, 2025, Geron reported its fourth-quarter financial results for fiscal 2024, revealing that Rytelo's growth had stagnated, attributing this to seasonality, competition, lack of awareness, and monitoring requirements [4]. - Following this announcement, Geron's stock price plummeted from $2.37 per share on February 25, 2025, to $1.61 per share on February 26, 2025, marking a decline of approximately 32.07% in one day [4]. Class Action Participation - Shareholders may be eligible to participate in the class action against Geron Corporation, with a deadline to file as lead plaintiff by May 12, 2025 [5]. - Shareholders can choose to remain absent class members without participating in the case [5]. Company Background - Robbins LLP is noted as a leader in shareholder rights litigation, focusing on helping shareholders recover losses and improve corporate governance since 2002 [6].

Core Viewpoint - Geron Corporation is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with claims that the company and its executives misled investors regarding the performance and market potential of its primary product, Rytelo [1][3]. Company Overview - Geron Corporation is a commercial-stage biopharmaceutical company focused on developing therapeutic products for oncology, with its main product being a telomerase inhibitor called imetelstat, marketed as Rytelo [2]. Allegations of the Lawsuit - The lawsuit alleges that Geron and its executives made false or misleading statements about the company's revenue outlook and growth potential, downplaying risks associated with seasonality and macroeconomic factors [3]. - It is claimed that the optimistic reports regarding Rytelo's launch success did not reflect the reality of market conditions, including competition and the need for ongoing monitoring, which significantly impacted patient starts [3]. - The lawsuit further asserts that Geron lacked the necessary market awareness for Rytelo, hindering its ability to meet the unmet medical needs, particularly among first-line patients [3]. Financial Impact - Following the announcement of its fourth-quarter financial results for fiscal year 2024 on February 26, 2025, which indicated that Rytelo's growth had stagnated due to various factors, Geron's stock price dropped by over 32% [4].

NEW YORK, March 27, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Geron Corporation (NASDAQ: GERN).Shareholders who purchased shares of GERN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/geron-corporation-loss-submission-form/?id=138835&from=4 CLASS PERIOD: June 7, 2024 to ...

NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Northern District of California on behalf of those who acquired Geron Corporation (“Geron” or the “Company”) (NASDAQ:GERN) securities during the period from June 7, 2024, through February 25, 2025 (“the Class Period”). Investors have until May 12, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit. [LEARN MO ...

Core Viewpoint - Securities class action lawsuits have been filed against Geron Corporation for allegedly misleading investors regarding its revenue outlook and product performance during the specified class period [1][3]. Group 1: Allegations Against Geron Corporation - Defendants allegedly created a false impression of possessing reliable information about Geron's revenue outlook while downplaying risks from seasonality and macroeconomic factors [3]. - Reports regarding the launch success and growth potential of Geron's primary product, RYTELO, were claimed to be overly optimistic and did not reflect the reality of market conditions [3]. - RYTELO reportedly lacked market penetration awareness, hindering Geron's ability to meet the unmet need for the drug among first-line patients and those outside academic settings [3]. - Statements made by the defendants about the company's business and prospects were claimed to be materially false and misleading [3]. Group 2: Legal Process for Investors - Geron investors can seek to be appointed as lead plaintiffs by May 12, 2025, through Kessler Topaz Meltzer & Check, LLP or other counsel [4]. - A lead plaintiff represents the interests of all class members and typically has the largest financial stake in the case [4]. - Investors can choose to remain absent class members without affecting their ability to share in any recovery [4].

NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Geron Corporation (NASDAQ: GERN). Shareholders who purchased shares of GERN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/geron-corporation-loss-submission-form/?id=138523&from=3  CLASS PERIOD: June 7, ...

Core Viewpoint - A class action lawsuit has been filed against Geron Corporation for alleged violations of securities laws, specifically related to misleading statements about the company's revenue outlook and the launch of its drug Rytelo [1][4]. Group 1: Lawsuit Details - The lawsuit is based on violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 [1]. - Investors who purchased Geron securities between June 7, 2024, and February 25, 2025, are encouraged to participate in the lawsuit [2]. - The class has not yet been certified, meaning potential participants are not currently represented by an attorney [3]. Group 2: Allegations Against Geron - The complaint alleges that Geron made false and misleading statements regarding its projected revenue and growth potential [4]. - The company reportedly provided an overly optimistic outlook on the launch and growth of Rytelo, failing to disclose that there was insufficient patient awareness to meet the claimed unmet need for the drug [4]. - As a result of these misleading statements, investors suffered damages when the truth about Geron's situation became known [4].